Market Place
Sourcing Support
BeOne Medicines Highlights Advancing Solid Tumor Pipeline at ASCO
01 Jun 2026 //
BUSINESSWIRE
BeOne: Brukinsa Sets CLL Standard with 78-Month Data at ASCO
29 May 2026 //
BUSINESSWIRE
BeOne Medicines: HERIZON-GEA Phase 3 Data Published in NEJM
27 May 2026 //
BUSINESSWIRE
BeOne Medicines to Present at Goldman Sachs Conference
26 May 2026 //
BUSINESSWIRE
BeOne Medicines Presents 60+ Abstracts at ASCO & EHA 2026
21 May 2026 //
BUSINESSWIRE
BeOne Medicines Launches Global Cancer Awareness Campaign
20 May 2026 //
BUSINESSWIRE
Cytovation Tests Getacatetide with Tislelizumab in Cancer
18 May 2026 //
GLOBENEWSWIRE
FDA Approves Blood Cancer Drugs From Beone And Taiho
15 May 2026 //
REUTERS
BeOne Wins Mantle Cell Lymphoma Approval
14 May 2026 //
BIOSPACE
Beone Medicines’ Beqalzi Receives Approval in US
13 May 2026 //
FDA
BeOne Medicines Unveils Q1 2026 Financials And Business Updates
06 May 2026 //
PHARMIWEB
BeOne Culls Five Cancer Programs And Autoimmune Phase 2
06 May 2026 //
ENDPOINTS
Senhwa Launches Global Study of CX-5461 + Tislelizumab
05 May 2026 //
PR NEWSWIRE
Huahui Health, BeOne Ink Global License for Oncology Drug HH160
30 Apr 2026 //
PR NEWSWIRE
FDA Grants Priority Review to TEVIMBRA in First-Line HER2+ GEA
29 Apr 2026 //
BUSINESSWIRE
BeOne Medicine Licenses Trispecific PD-1/CTLA-4/VEGF Antibody
28 Apr 2026 //
ENDPOINTS
BeOne Medicines to Report Q1 2026 Results on May 6
22 Apr 2026 //
BUSINESSWIRE
China Signs Off On Amgen`s Imdelltra
10 Apr 2026 //
FIERCE PHARMA
BeOne Launches Tislelizumab For Advanced Oesophageal Cancer
10 Mar 2026 //
PHARMIWEB
Beone Medicines To Present At Upcoming Investor Conferences
17 Feb 2026 //
BUSINESSWIRE
BeOne Medicines To Release 2025 Q4 And Full-Year Financials
11 Feb 2026 //
BUSINESSWIRE
InSysBio to Announce a Collaborative Project with BeOne Medicines
28 Jan 2026 //
PR NEWSWIRE
FDA Issues First Two Untitled Letters In 2026 Enforcement Drive
14 Jan 2026 //
RAPS
BeOne Medicines Spotlights Global Oncology at 44th JPM Conference
13 Jan 2026 //
PHARMIWEB
TEVIMBRA Acquired By ZIIHERA For HER2+ Advanced GEA
06 Jan 2026 //
BUSINESSWIRE
Beone Medicines To Present At J.P. Morgan Healthcare Conference
23 Dec 2025 //
BUSINESSWIRE
Beone Medicines Receives FDA Fast Track For BGB-B2033
18 Dec 2025 //
PHARMIWEB
Senhwa & BeOne Medicines Ink Deal Targeting Cold Tumors
10 Dec 2025 //
PR NEWSWIRE
BRUKINSA Achieves 74% 6-Year PFS In Treatment-Naïve Cll
08 Dec 2025 //
PHARMIWEB
Sonrotoclax Shows Promise in B-Cell Malignancies at ASH 2025
07 Dec 2025 //
BUSINESSWIRE
FDA Grants Priority Review To Sonrotoclax
26 Nov 2025 //
BUSINESSWIRE
Beone Medicines Highlights B-Cell Malignancy Leadership At ASH
20 Nov 2025 //
BUSINESSWIRE
Positive Ph3 Data Support ZIIHERA as HER2 Therapy-of-Choice
17 Nov 2025 //
BUSINESSWIRE
BeOne Medicines Reveals Q3 2025 Financials & Business Updates
06 Nov 2025 //
BUSINESSWIRE
Insysbio To Announce Its Collaboration With Beone Medicines
29 Oct 2025 //
PR NEWSWIRE
Beone Medicines To Present At Upcoming Investor Conferences
28 Oct 2025 //
BUSINESSWIRE
Beone Medicines To Release Q3 2025 Financial Results On Nov 6
22 Oct 2025 //
BUSINESSWIRE
Beone Medicines Unveils TEVIMBRA Data In Lung Cancer At ESMO 2025
20 Oct 2025 //
PHARMIWEB
Beone Medicines` Sonrotoclax Receives FDA Breakthrough Therapy
13 Oct 2025 //
PHARMIWEB
Abbvie, Beone End BTK Inhibitor Patent Fight
02 Oct 2025 //
FIERCE PHARMA
BeOne Medicines Reports Sonrotoclax Success in Relapsed Lymphoma
29 Aug 2025 //
PHARMAWEB
EC Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC
27 Aug 2025 //
BUSINESSWIRE
BeOne Bags $885 M in Royalty Deal on Amgen`s Imdelltra
26 Aug 2025 //
FIERCE PHARMA
Europe Approves BeOne`s BRUKINSA Tablet for All Indications
21 Aug 2025 //
BUSINESSWIRE
BeOne Medicines Reveals Q2 2025 Financial Results & Updates
06 Aug 2025 //
BUSINESSWIRE
BeOne Gets PRIME Designation for BGB-16673 in Macroglobulinemia
31 Jul 2025 //
BUSINESSWIRE
Be One`s Tevimbra Gets Positive Chmp Opinion for NSCLC Treatment
28 Jul 2025 //
BUSINESSWIRE
BeOne Medicines` Q2 2025 Financial Results Due August 6
16 Jul 2025 //
BUSINESSWIRE
European Commission Approve Tevimbra for Nasopharyngeal Carcinoma
10 Jul 2025 //
BUSINESSWIRE
Biocytogen, BeOne Ink Antibody Licensing Deal
09 Jul 2025 //
BUSINESSWIRE
BeOne Medicine Showcases Oncology Pipeline at R&D Day
26 Jun 2025 //
BUSINESSWIRE
BeOne Medicines gets CHMP Nod for Brukinsa tablet formulation
25 Jun 2025 //
BUSINESSWIRE
Glenmark Pharmaceuticals launches TEVIMBRA in India
25 Jun 2025 //
INDPHARMAPOST
BeOne Medicines Presents Breakthrough Data in CLL and MCL at EHA
12 Jun 2025 //
BUSINESSWIRE
U.S. Fda Approves Tablet Formulation of Brukinsa
11 Jun 2025 //
BUSINESSWIRE
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
11 Jun 2025 //
BUSINESSWIRE
Glenmark Pharma to launch DCGI-approved Brukinsa in India
11 Jun 2025 //
INDPHARMAPOST
BeiGene Gets CHMP Nod for Tevimbra in Nasopharyngeal Cancer
27 May 2025 //
BUSINESSWIRE
BeiGene Presents Cancer Research at ASCO 2025
22 May 2025 //
BUSINESSWIRE
BeiGene Highlights Hematology Portfolio at EHA 2025
14 May 2025 //
BUSINESSWIRE
